Blueprint Medicines share price today

(BPMC)

Blueprint Medicines share price is $90.14 & ₹7,659.74 as on 21 Dec 2024, 2.30 'hrs' IST

$90.14

▲

1.21

(1.36%)

Market is closed - opens 8 PM, 23 Dec 2024

View live Blueprint Medicines share price in Dollar and Rupees. Guide to invest in Blueprint Medicines from India. Also see the sentimental analysis on Indian investors investing in Blueprint Medicines. Get details on the Indian mutual funds that are investing in Blueprint Medicines. Get Analyst recommendations and forecasts along with all the Blueprint Medicines's financials.

Blueprint Medicines share price movements

Today's Low: $87.99
Today's High: $90.93
$90.14
2.38%
Downside
Day's Volatility :3.23%
Upside
0.87%
52 Weeks Low: $72.24
52 Weeks High: $121.90
$90.14
19.86%
Downside
52 Weeks Volatility :40.74%
Upside
26.05%

Blueprint Medicines Returns

Period	Blueprint Medicines Corp	Sector (Health Care)	Index (Russel 2000)
3 Months	0.09%	-11.1%	0.0%
6 Months	-15.04%	-6.0%	0.0%
1 Year	1.47%	2.7%	0.0%
3 Years	-17.03%	0.6%	-19.7%

Blueprint Medicines Key Statistics

in dollars & INR

Previous Close	$88.93
Open	$88.12
Today's High	$90.93
Today's Low	$87.9902
Market Capitalization	$5.6B
Today's Volume	$1.1M
52 Week High	$121.9
52 Week Low	$72.24
Revenue TTM	$434.4M
EBITDA	$-262.1M
Earnings Per Share (EPS)	$-2.09
Profit Margin	-29.48%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-49.66%

How to invest in Blueprint Medicines from India?

It is very easy for Indian residents to invest directly in Blueprint Medicines from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Blueprint Medicines stock in both Indian Rupees (INR) and US Dollars (USD). Search for Blueprint Medicines or BPMC on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Blueprint Medicines or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Blueprint Medicines shares which would translate to 0.009 fractional shares of Blueprint Medicines as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Blueprint Medicines, in just a few clicks!

Returns in Blueprint Medicines for Indian investors in Rupees

Investment Value

₹1,00,000

Blueprint Medicines investment value today

Current value as on today

₹1,03,671

Returns

₹3,671

(+3.67%)

Returns from Blueprint Medicines Stock

₹1,475 (+1.47%)

Dollar Returns

₹2,196 (+2.2%)

Indian investors sentiment towards Blueprint Medicines

-50%

Period: Sep 21, 2024 to Dec 20, 2024. Change in 30 Days versus previous period

Search volume for Blueprint Medicines on INDmoney from India has reduced in the last 30 days as on Dec 21, 2024. -50% less investors are searching Blueprint Medicines in the last 30 days versus the previous period.

Global Institutional Holdings in Blueprint Medicines

Vanguard Group Inc
10.52%
BlackRock Inc
10.46%
T. Rowe Price Associates, Inc.
8.48%
FMR Inc
7.11%
Wellington Management Company LLP
6.24%
State Street Corp
4.35%

Analyst Recommendation on Blueprint Medicines

Buy

73%Buy

17%Hold

8%Sell

Based on 23 Wall street analysts offering stock ratings for Blueprint Medicines(by analysts ranked 0 to 5 stars)

Based on 23 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Blueprint Medicines

What analysts predicted

Upside of 39.32%

Current:

$90.14

Target:

$125.58

Insights on Blueprint Medicines

Price Movement
In the last 6 months, BPMC stock has moved down by -13.5%
Decreasing Revenue
Revenue is down for the last 2 quarters, 138.15M → 128.18M (in $), with an average decrease of 7.2% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, 89.13M → -56.27M (in $), with an average decrease of 84.3% per quarter
BPMC vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 35.5% return, outperforming this stock by 30.6%
BPMC vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 23.0% return, outperforming this stock by 38.3%
Price to Sales
ForBPMC every $1 of sales, investors are willing to pay $12.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.9 for every $1 of sales.

Blueprint Medicines Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$44.5M	↑ 107.79%
Net Income	$-236.6M	↑ 59.76%
Net Profit Margin	-531.53%	↑ 159.77%

	FY19	Y/Y Change
Revenue	$66.5M	↑ 49.39%
Net Income	$-328.7M	↑ 38.9%
Net Profit Margin	-494.2%	↑ 37.33%

	FY20	Y/Y Change
Revenue	$793.7M	↑ 1093.37%
Net Income	$313.9M	↓ 195.49%
Net Profit Margin	39.54%	↑ 533.74%

	FY21	Y/Y Change
Revenue	$180.1M	↓ 77.31%
Net Income	$-644.1M	↓ 305.2%
Net Profit Margin	-357.67%	↓ 397.21%

	FY22	Y/Y Change
Revenue	$204.0M	↑ 13.3%
Net Income	$-557.5M	↓ 13.44%
Net Profit Margin	-273.24%	↑ 84.43%

	FY23	Y/Y Change
Revenue	$249.4M	↑ 22.22%
Net Income	$-507.0M	↓ 9.06%
Net Profit Margin	-203.3%	↑ 69.94%

	Q2 FY23	Q/Q Change
Revenue	$57.6M	↓ 9.03%
Net Income	$-132.8M	↑ 2.5%
Net Profit Margin	-230.66%	↓ 25.94%

	Q3 FY23	Q/Q Change
Revenue	$56.6M	↓ 1.74%
Net Income	$-133.7M	↑ 0.69%
Net Profit Margin	-236.38%	↓ 5.72%

	Q4 FY23	Q/Q Change
Revenue	$72.0M	↑ 27.21%
Net Income	$-110.9M	↓ 17.05%
Net Profit Margin	-154.14%	↑ 82.24%

	Q1 FY24	Q/Q Change
Revenue	$96.1M	↑ 33.57%
Net Income	$89.1M	↓ 180.36%
Net Profit Margin	92.74%	↑ 246.88%

	Q2 FY24	Q/Q Change
Revenue	$138.2M	↑ 43.74%
Net Income	$-50.0M	↓ 156.09%
Net Profit Margin	-36.19%	↓ 128.93%

	Q3 FY24	Q/Q Change
Revenue	$128.2M	↓ 7.22%
Net Income	$-56.3M	↑ 12.57%
Net Profit Margin	-43.9%	↓ 7.71%

	FY18	Y/Y Change
Profit	$-199.1M	↑ 61.53%

	FY19	Y/Y Change
Profit	$66.5M	↓ 133.41%

	FY20	Y/Y Change
Profit	$793.3M	↑ 1092.73%

	FY21	Y/Y Change
Profit	$162.1M	↓ 79.56%

	FY22	Y/Y Change
Profit	$186.2M	↑ 14.85%

	FY23	Y/Y Change
Profit	$236.6M	↑ 27.04%

	Q2 FY23	Q/Q Change
Profit	$55.2M	↓ 8.09%

	Q3 FY23	Q/Q Change
Profit	$52.0M	↓ 5.85%

	Q4 FY23	Q/Q Change
Profit	$70.2M	↑ 34.9%

	Q1 FY24	Q/Q Change
Profit	$88.1M	↑ 25.58%

	Q2 FY24	Q/Q Change
Profit	$126.9M	↑ 44.07%

	Q3 FY24	Q/Q Change
Profit	$126.3M	↓ 0.55%

	FY18	Y/Y Change
Operating Cash Flow	$-175.0M	↑ 46.01%
Investing Cash Flow	$-161.1M	↑ 112.38%
Financing Cash Flow	$4.5M	↓ 99.18%

	FY19	Y/Y Change
Operating Cash Flow	$-278.0M	↑ 58.86%
Investing Cash Flow	$-16.5M	↓ 89.78%
Financing Cash Flow	$340.6M	↑ 7547.91%

	FY20	Y/Y Change
Operating Cash Flow	$387.0M	↓ 239.21%
Investing Cash Flow	$-434.2M	↑ 2537.25%
Financing Cash Flow	$617.8M	↑ 81.35%

	FY21	Y/Y Change
Operating Cash Flow	$-298.7M	↓ 177.16%
Investing Cash Flow	$-225.9M	↓ 47.99%
Financing Cash Flow	$50.7M	↓ 91.79%

	FY22	Y/Y Change
Operating Cash Flow	$-502.3M	↑ 68.18%
Investing Cash Flow	$-149.5M	↓ 33.79%
Financing Cash Flow	$561.8M	↑ 1007.76%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-130.5M	↑ 6.11%
Investing Cash Flow	$32.1M	↓ 81.44%
Financing Cash Flow	$5.3M	↑ 0.0%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-104.5M	↓ 19.92%
Investing Cash Flow	$-9.6M	↓ 129.89%
Financing Cash Flow	$98.4M	↑ 1757.29%

Blueprint Medicines Technicals Summary

Sell

Neutral

Buy

Blueprint Medicines is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Blueprint Medicines Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Blueprint Medicines Corp	-6.71%	-15.04%	1.47%	-17.03%	10.18%
Regeneron Pharmaceuticals, Inc.	-5.73%	-34.03%	-17.11%	13.66%	87.56%
Biontech Se	4.48%	30.56%	7.36%	-56.46%	225.6%
Alnylam Pharmaceuticals, Inc.	-0.55%	10.11%	28.49%	30.99%	109.19%
Vertex Pharmaceuticals Incorporated	-11.79%	-16.36%	-1.97%	78.33%	80.59%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Blueprint Medicines Corp	NA	NA	0.0	-1.4	-0.5	-0.15	NA	4.93
Regeneron Pharmaceuticals, Inc.	17.51	17.51	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.17	0.55	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Blueprint Medicines Corp	Buy	$5.6B	10.18%	NA	-29.48%
Regeneron Pharmaceuticals, Inc.	Buy	$77.8B	87.56%	17.51	33.61%
Biontech Se	Buy	$26.7B	225.6%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$30.8B	109.19%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$102.1B	80.59%	32.84	-4.51%

Blueprint Medicines Dividend announcements

Blueprint Medicines Earnings
Blueprint Medicines’s price-to-earnings ratio stands at None
Read More

About Blueprint Medicines

blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development

Organization	Blueprint Medicines
Employees	638
CEO	Ms. Kathryn Haviland M.B.A.
Industry	Health Technology

Management People of Blueprint Medicines

Name	Title
Ms. Kathryn Haviland M.B.A.	President, CEO & Director
Mr. Alexis A. Borisy A.M.	Co-Founder & Director
Ms. Christina Rossi M.B.A.	Chief Operating Officer
Dr. Percy H. Carter M.B.A., Ph.D.	Chief Scientific Officer
Dr. Fouad Namouni M.D.	President of Research & Development
Ms. Ariel Hurley	Senior VP, Finance & Principal Accounting Officer
Ms. Jenna Cohen	Senior Director & Head of Investor Relations
Ms. Tracey L. McCain Esq.	Executive VP, Chief Legal & Compliance Officer and Secretary
Ms. Debra Durso-Bumpus	Chief People Officer
Mr. Julian Charles Baker	Senior Vice President of Corporate Affairs

Important FAQs about investing in Blueprint Medicines from India :

What is Blueprint Medicines share price today?

Blueprint Medicines share price today stands at $90.14, Open: $88.12 ; Previous Close: $88.93 ; High: $90.93 ; Low: $87.99 ; 52 Week High: $121.90 ; 52 Week Low: $72.24. The stock opens at $88.12, after a previous close of $88.93. The stock reached a daily high of $90.93 and a low of $87.99, with a 52-week high of $121.90 and a 52-week low of $72.24.

Can Indians buy Blueprint Medicines shares?

Yes, Indians can invest in the Blueprint Medicines (BPMC) from India.

With INDmoney, you can buy Blueprint Medicines at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Blueprint Medicines at zero transaction cost.

How can I buy Blueprint Medicines shares from India?

It is very easy to buy Blueprint Medicines from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Blueprint Medicines be purchased?

Yes, you can buy fractional shares of Blueprint Medicines with INDmoney app.

What are the documents required to start investing in Blueprint Medicines stocks?

To start investing in Blueprint Medicines, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.